Kornimate/medical-research-clean huggingface dataset:
factors associated with chronic respiratory failure in obesity

Conditions: Obesity; Obesity Hypoventilation Syndrome

Summary: some overweight individuals develop problems with their breathing such that they gradually breathe less and less. this leads to a lack of oxygen and a buildup of carbon dioxide in the blood, called ventilatory failure. as a consequence, if such a person develops a chest infection, they are more likely to become seriously ill and need intensive care. in addition they are much more likely to develop severe complications during and following operations. this problem can be treated with a machine at home used overnight to help breathing. it is interesting that ventilatory failure only happens in some overweight individuals, and the investigators do not understand what factors make this complication develop. there are a number of theories: for example the distribution of the fat, additional lung disease (such as asthma), the addition of obstructive sleep apnoea, a condition when there are periods of cessation of breathing overnight (which is more common in obese individuals), weak muscles of breathing (perhaps due to fatty infiltration of muscles or vitamin d deficiency), and other hormonal changes. the investigators intend to measure many potential factors in a range of overweight individuals, some who have ventilatory failure, and some who do not, to try and work out which are the important factors that cause this problem. if the investigators can identify such factors, then this will help predict in advance who is at risk from chest infections and during operations; thus allowing for earlier provision of an overnight breathing machine. this should reduce complications and potentially deaths in such individuals.

to test the hypothesis that in obese patients with obesity-hypoventilation (ohs) there are specific factors related to the development of ventilatory failure, compared to obese subjects not in ventilatory failure

Eligibility criteria:
inclusion criteria: * obese (bmi \> 30) with or without obesity hypoventilation * (ohs) (18 - 85yrs) * admitted for management of their ohs * attending the sleep and ventilation clinic * being assessed for bariatric surgery * willing and able to give informed consent for participation in the study * men and women aged 18 - 85 years exclusion criteria: * respiratory acidosis ph \<7.30 * severe untreated hypothyroidism * current treatment with theophylline * current treatment with diuretics * severe restrictive or obstructive lung disease (\<30% predicted) * severe comorbidities such as moderate/severe copd, left sided heart failure, and primary cns or neuromuscular diseases * contraindications to mri scanning * contraindications to dxa scanning * previous participant in research in the last 12 months

Keywords: obesity
comparison of different doses of 131i in severe graves' hyperthyroidism

Conditions: Graves Disease

Summary: the purpose of this study is to determine whether higher doses of radioiodine increase treatment efficacy in severe graves' disease.

graves' disease (gd) is the most frequent cause of hyperthyroidism, affecting mainly women aged 40-60 years. radioiodine (¹³¹i), introduced in 1941, has become a cornerstone in the treatment of gd hyperthyroidism. because of its safety, low costs and rapid effect, it is considered a first line therapy in the united states. however, treatment failure occurs in about 15-25% of patients treated with radioiodine. patients not cured with the first dose of radioiodine usually present severe hyperthyroidism, characterized by large goiter, high 24-hour radioiodine uptake (24h-raiu) and very high levels of thyroid hormones. we have previously shown that large goiter (≥48ml) is an independent predictor of treatment failure. in these patients, the therapeutic failure was 40.0% while in patients with smaller goiter was only 6.5% (p=0.005; unpublished). it is generally accepted that higher doses of radioiodine improves cure rates. indeed, a recent meta-analysis found a correlation between radioiodine dose and therapeutic success in gd patients. to our knowledge, there are no published studies evaluating cure rates with different radioiodine doses in severe gd.

Eligibility criteria:
inclusion criteria: * consecutive patients with a recent diagnosis of graves' disease and goiter ≥ 48 ml, attending the endocrine division at hospital de clinicas de porto alegre are eligible. exclusion criteria: * patients with previous treatment with radioiodine or thyroidectomy, * signs of moderate or severe ophthalmopathy (proptosis \> 22 mm, ophthalmoplegia, chemosis, or lagophthalmos), * severe heart disease (symptomatic coronary heart disease, class iii heart failure, new york heart association criteria), * debilitating conditions, and * large and compressive goiters (\> 150 g).

Keywords: graves disease hyperthyroidism radioiodine clinical trial
:effects of pharmaceutical care in stroke patients

Conditions: Stroke

Summary: to evaluate the effects of the 1-year pharmaceutical care program offered by the clinical pharmacist to the patients admitted to the neurology service with the diagnosis of stroke, on medication adherence, quality of life, and clinical outcomes of the patients.

the study was conducted as a parallel randomized controlled study in the neurology clinic of a university hospital in turkey. patients were randomly assigned to intervention and usual care groups. while the patients in the usual care group are given routine health services by the neurologist during their hospitalization and for 1 year after discharge; in addition to these routine services, the intervention group was provided with pharmaceutical care by a clinical pharmacist during the same period. the study was always conducted by the same neurologist and clinical pharmacist. patient medication adherence, quality of life, and clinical parameters were evaluated at the beginning of the study and at the 12th month.

Eligibility criteria:
inclusion criteria: * being diagnosed with stroke, * being 18 years old or older, * being in the cognition to receive the training to be given exclusion criteria: * not having adequate cognitive function such as dementia, * being pregnant, lactating, * having cancer.
hypertension management using remote patient monitoring: study 2

Conditions: Hypertension

Summary: the investigators will conduct a pragmatic pilot test of a remote patient monitoring system (rpm) for blood pressure measurement for medicare patients with hypertension with and without the support of a care management program. the primary objective is to better understand how patients' remote monitoring of blood pressure and the direct transmission of this data to a healthcare system's ehr can be used by the patient and the care team to support optimal hypertension care and whether the addition of active care management increases the use of rpm and improvements in blood pressure. this pilot study will be conducted in four northwestern medical group (nmg) primary care practices. two practices will have rpm available for primary care physicians to order for their eligible medicare patients and two practices will also receive the support of a care management program to assist with patient enrollment, blood pressure monitoring and taking action in the setting of uncontrolled blood pressure. the investigators will conduct a pragmatic non-blinded, non-randomized pilot study with contemporaneous controls among nmg outpatient clinics that provide adult primary care. they will make comparisons of data obtained through the course of routine care delivery from pilot and non-pilot practices.


Eligibility criteria:
inclusion criteria:we will use these criteria to determine which patients will be included or excluded in the study analytic data set. general inclusion criteria: * adults aged 65 to 85 years at the time of the study start date * receive their primary care from an eligible northwestern medicine clinic site * one or more office or telehealth visits in the year preceding the study start date inclusion criteria primary population: * last two office blood pressures ≥140 mm hg systolic or ≥90 mmhg diastolic * diagnosis of hypertension in the year preceding the study start date (problem list or encounter diagnosis) inclusion criteria for secondary population * meet criteria for primary population or * diagnosed hypertension but did not have the last two office blood pressures ≥140 mm hg systolic or ≥90 mmhg diastolic or * no diagnosis of hypertension in the past year but did have the last office blood pressure ≥140 mm hg systolic or ≥90 mmhg diastolic exclusion criteria: * persistent atrial fibrillation as indicated in the electronic health record (ehr) * stage iv or more severe kidney disease, defined as estimated glomerular filtration rate \<30 per 1.73 m2 or currently on renal replacement therapy (i.e. hemodialysis or peritoneal dialysis) * diagnosis of dementia as indicated in the electronic health record
recombinant human endostatin combined with np in neoadjuvant chemotherapy of stage ⅲa nsclc

Conditions: Non Small Cell Lung Cancer

Summary: this study mainly to observe the anti angiogenic drugs endostatin (endostar) combined with vinorelbine and cisplatin (np) as neoadjuvant therapy in patients with non small cell lung cancer clinical efficiency and safety. through anti angiogenesis therapy combined with neoadjuvant chemotherapy improve the treatment of neoadjuvant therapy in tumor response rate and the rate of resection, at the same time, the study before and after the anti angiogenesis therapy in patients with peripheral blood circulation endothelial cells(cecs), levels of endothelial progenitor cells（epc）, micro vascular density（mvd） and vascular endothelial growth factor(vegf) expression level, to understanding the correlation between the clinical efficacy of anti angiogenesis therapy combined with chemotherapy and the change of all these markers. in order to find the reference basis for the prediction of the effect of curative effect. the changes of blood volume, blood flow and vascular permeability of the lung cancer before and after treatment with ct perfusion imaging are studied.


Eligibility criteria:
inclusion criteria: * the pathology proved to be non small cell lung cancer (must be histologically). * at present, the patients with ⅲa stage (n2) were evaluated by the assistant examination; * the patients were evaluated by imaging, laboratory examination and other examination; * without chemotherapy or anti angiogenic therapy; * there can be measured lesions * informed consent. exclusion criteria: * pregnant, lactating women, or patients with fertility but did not take contraceptive measures. * severe infection. * severe heart disease.neuropsychiatric disorders, which is not easy to control. * severe diabetes. * there is obvious bleeding tendency. * the 5 years history of other tumors

Keywords: lung cancer anti angiogenesis therapy survival
tourniquet use in hallux valgus surgery

Conditions: Hallux Valgus

Summary: prospective, single-center, randomized interventional clinical trial of tourniquet use in hallux valgus surgery. patients will be their own controls.


Eligibility criteria:
inclusion criteria: * patients over 18 who has been informed and has signed the consent form * patient to be operated on for bilateral hallux valgus with no difference in the procedure performed between the 2 feet, the deformity must not differ by more than 10° (angle m1p1) between the 2 sides. * surgery planned on the same day for both feet exclusion criteria: * arthritic hallux valgus requiring arthrodesis * inflammatory pathology (rheumatoid arthritis, etc.)

Keywords: hallux valgus tourniquet
effects of a kappa agonist on hot flashes in menopausal women

Conditions: Treatment of Menopausal Hot Flashes

Summary: studies suggest that kappa agonists (ka) and peripherally restricted kappa agonists (prkas) may affect thermoregulation. this pilot study has the aim to establish proof of concept regarding efficacy of an oral kappa agonist (ka) for the treatment of menopausal hot flashes.

to establish proof of concept regarding efficacy of an oral kappa agonist (ka), pentazocine/ naloxone 50/0.5 mg, for the treatment of menopausal hot flashes. to gather data in support of a future proposal to study the safety and efficacy of a prka, a type of ka, for amelioration of menopausal hot flashes.

Eligibility criteria:
inclusion criteria: 1. healthy women 45-60 years of age; 12 months amenorrhea 2. documentation of \> 8 moderate to severe, daily hot flashes during one week of baseline monitoring using daily diaries 3. availability of a family member or friend to drive participant home following clinic visits exclusion criteria: 1. use of hormonal prescription medication or supplements for vasomotor symptoms (vms) 2. use of narcotics 3. use of ssri (selective serotonin reuptake inhibitor)/snri (serotonin-norepinephrine reuptake inhibitors), gabapentin, maoi (monoamine oxidase inhibitor), anti-epileptics, sedatives 4. history of polycystic ovarian syndrome or hirsutism 5. current history of depression 6. any chronic or acute medical illnesses including renal, hepatic, pulmonary diseases, or seizures 7. substance abuse 8. severe corn allergy 9. known allergic reaction to pentazocine or naloxone 10. presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data 11. hysterectomy 12. use of anticholinergic medications 13. lactating or pregnant

Keywords: hot flashes menopause kappa agonist
bipolar disorder and oxidative stress injury mechanism - clinical big data analysis based on machine learning

Conditions: Bipolar Disorder

Summary: this study is a single-center, retrospective, cross-sectional study. we plan to work with our network information center to analysis the related indicators of oxidative stress injury in patients with bipolar disorder based on oxidative stress data. during the study, machine learning was used as a data analysis method to screen out the biomarker risk factors with sensitivity and specificity for early recognition of bipolar disorder from major depression disorder with oxidative stress injury as the core. and then build up effective clinical predictive models for early identification of bipolar disorder, which can predict the early quantitative probabilistic of the onset of bipolar disorder.


Eligibility criteria:
inclusion criteria: * age is not limited * gender is not limited * meets the diagnostic criteria for bipolar disorder of icd-10 f31,f32 and its sub-categories * has relevant his system data that can be utilized. exclusion criteria: * patients who did not meet the appeal diagnosis after three-level rounds of ward * patients who met the above three diagnoses but had severe data loss (missing value ≥ estimated data value of 30%)

Keywords: bipolar disorder machine learning
substance use and lifestyle-related health problems in ageing patients in omt treatment

Conditions: Substance Use Disorders; Opioid Use Disorder; Tobacco Use; Health, Subjective; Mental Health Impairment

Summary: the overall aim of the study is to explore substance use, tobacco use and lifestyle-related health problems among ageing patients in opioid maintenance treatment (omt), and other sud treatment. the study will use already collected data from the multi-center, longitudinal, observational norcomt study (norwegian cohort of patients in opioid maintenance treatment and other drug treatment study). norcomt is the largest longitudinal study of sud patients in norway. the data consists of data from omt and other substance use disorders (sud) treatment (n=548).

the overall aim of the study is to explore substance use, tobacco use and lifestyle-related health problems among ageing patients in opioid maintenance treatment (omt), and other sud treatment. the study will use already collected data from the multi-center, longitudinal, observational norcomt (norwegian cohort of patients in opioid maintenance treatment and other drug treatment) study. norcomt is the largest longitudinal study of sud patients in norway. the data consists of data from omt and other substance use disorders (sud) treatment (n=548). the present doctoral research degree project is financed by the southern and eastern norway regional health authority, and hosted by sørlandet hospital in collaboration with the norwegian centre for addiction research (seraf). ethical approval for analysis of norcomt data and for the planned registry data linkages of norcomt data has been granted by the norwegian regional ethics committee (rek 2012/1131).

Eligibility criteria:
inclusion criteria: * admittance to a substance use disorder treatment facility, either standardized opioid maintenance treatment (omt) or other substance use disorder treatment (in-patient) exclusion criteria: * none
immunologic markers for the differential diagnosis between uveitis-tbc and uveitis-sarc (tbc-sarc)

Conditions: Uveitis Tuberculous; Uveitis Sarcoid

Summary: today there are no tests that allow to make a precise differential diagnosis between uveitis from presumed tuberculous origin and uveitis by sarcoidosis. therefore, with this study, investigators aim to identify, in the aqueous humor and in the blood of participants (patients that suffering from one of these two forms of uveitis) the presence of immunologic markers that distinguish between uveitis of tuberculous etiology and uveitis by sarcoidosis.

both tuberculosis and sarcoidosis are chronic, multi-systemic and granulomatous pathologies that have very similar pulmonary and extra-pulmonary manifestations, and even in the case of ocular involvement it has been shown that many features of intraocular tb can also be found in participants with ocular sarcoidosis. in this monocentric observational study investigators are asking to the participants with granulomatous uveitis, in which a tuberculosis or sarcoidosis origin is suspected and who will have undergo paracentesis of the anterior chamber, to grant part of the aqueous humor and a blood sample for this study. the collected samples will be analyzed as follow: 1. determination of the concentration of various cytokines, chemokines and growth factors in aqueous humor and in the plasma. 2. analysis of the mononuclear cells ( t helper lymphocytes cd3+ (cd3 is the acronym of cluster of differentiation 3: a glycoprotein found on the surface of immune cells) and cd4+ ((cd4 is the acronym of cluster of differentiation 4), t cytotoxic lymphocytes cd3+ cd8+ (cd8 is the acronym of cluster of differentiation 8) , b lymphocytes cd19+ (cd19 is the acronym of cluster of differentiation 19), natural killer lymphocytes cd56+ (cd56 is the acronym of cluster of differentiation 56) and cd3- and monocytes cd14+ (cd14 is the acronym of cluster of differentiation 14) present in the aqueous humor by cytofluorimetry. 3. evaluation of the presence of anti-human hsp70 antibodies in plasma samples by western blot immunoprecipitation assays. 4. whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells in aqueous humor with epitopes of tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants.

Eligibility criteria:
inclusion criteria: * patients with diagnosis of uveitis of tuberculous etiology or patients with diagnosis of uveitis of suspect sarcoidosis or patients with diagnosis of uveitis of undifferentiated origin (tuberculosis/sarcoidosis) exclusion criteria: * patients suffering from non-granulomatous uveitis.
pharmacokinetics and pharmacodynamics of nasally applied esketamine

Conditions: Pain

Summary: the purpose of this study is the determination of blood concentration and the effectiveness of esketamine after nasal application.


Eligibility criteria:
inclusion criteria: * male * age ≥18 years ≤ 45 years * healthy * non-smoking * bmi 18-27 exclusion criteria: * abuse of drugs * known or supposed hypersensitivity and/or contraindication against ketamine or additives * participation of another clinical study within the last 30 days * chronic obstructed nose breathing or nasal polyps * dug allergy * blood donation within the last two months

Keywords: pharmacokinetics ketamine anesthetics, dissociative
buprenorphine maintenance dose schedule and treatment setting - 1

Conditions: Opioid-Related Disorders; Substance-Related Disorders

Summary: the purpose of this study is to assess optimal dosage of buprenorphine on a thrice weekly schedule in a pilot clinical trial.


Eligibility criteria:
please contact site for information.

Keywords: opioid dependence
a study to evaluate the safety and performance of arterx™ vascular sealant in sealing synthetic arterial grafts

Conditions: Vascular Disease

Summary: a prospective, multi-center study to evaluate the safety and performance outcomes of the arterx vascular sealant when used for prophylactic sealing of suture lines at the anastomosis between native vessel and synthetic vascular grafts.


Eligibility criteria:
inclusion criteria: 1. the subject must be ≥ 18 years old 2. the subject must be scheduled for surgical placement of a synthetic graft for large vessel repair/ arterial reconstruction/ hemodialysis access. 3. the subject has no child bearing potential or has a negative serum or urine pregnancy test within 7 days of the index procedure. 4. the subject is willing and able to be contacted for minimum of 6 weeks follow up. 5. the subject or guardian must provide written informed consent using a form that is reviewed and approved by the ethics committee. exclusion criteria: 1. the subject has a known hypersensitivity or contraindication to heparin, bovine or seafood products. 2. the subject has a history of bleeding diathesis or coagulopathy, or will refuse blood transfusion. 3. the subject is currently enrolled in this, or another investigational device or drug trail that has not completed the required follow-up period. 4. arterx vascular sealant should not be used in patients who have exhibited an allergic reaction to materials of shellfish or bovine origin.
different treatments with the trv reposition chair

Conditions: Benign Paroxysmal Positional Vertigo

Summary: to investigate which treatment option (reposition maneuver) with the trv chair that is the most effective in patients diagnosed with benign paroxysmal positional vertigo (bppv). subtypes of bppv will be examined after randomization to specific treatments.

patients diagnosed with bppv with subtypes of either posterior canalolithiasis or lateral cupulolithiasis will we considered for enrollment. each subgroup of patients will undergo randomization for a specific treatment.

Eligibility criteria:
inclusion criteria: * age above 18 years of age * medical history compatible with bppv * verification of bppv with either dix-hallpike maneuver or supine roll test. exclusion criteria: * former treatment with a repositional chair * not being able to participate or cooperate in the treatment provided by the trv repositional chair

Keywords: trv reposition chair epley maneuvre